Pharma Tariffs: Minimal Risk for Domestic Companies, Says Mizuho Strategist

Impact of Pharma Tariffs on Companies

• 🎯 The recent announcement regarding pharma tariffs has had a minimal impact on big-cap pharmaceutical stocks.
• 💡 Jared Holz, healthcare equity strategist at Mizuho, agrees that the impact on large companies is negligible.

Risks for Smaller and Mid-Cap Players

• ⚠️ Concerns exist about the potential devastating impact on smaller companies that do not have US manufacturing facilities.
• 📌 However, many biotech companies that Mizuho follows are primarily domestic, even if they have R&D operations overseas.

Domestic Manufacturing as a Buffer

• 🏠 Companies with facilities located in the US and those investing domestically are largely out of the fray regarding these tariffs.
• ✅ The net impact on the pharmaceutical sector was positive, with most companies being domestic and therefore not facing significant risk.